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Background: Between 8% and 22% of female carriers of DMD mutations exhibit clinical symptoms of variable
severity. Development of symptoms in DMD mutation carriers without chromosomal rearrangements has been
attributed to skewed X-chromosome inactivation (XCI) favouring predominant expression of the DMD mutant allele.
However the prognostic use of XCI analysis is controversial. We aimed to evaluate the correlation between
X-chromosome inactivation and development of clinical symptoms in a series of symptomatic female carriers of
dystrophinopathy.
Methods: We reviewed the clinical, pathological and genetic features of twenty-four symptomatic carriers covering
a wide spectrum of clinical phenotypes. DMD gene analysis was performed using MLPA and whole gene
sequencing in blood DNA and muscle cDNA. Blood and muscle DNA was used for X-chromosome inactivation (XCI)
analysis thought the AR methylation assay in symptomatic carriers and their female relatives, asymptomatic carriers
as well as non-carrier females.
Results: Symptomatic carriers exhibited 49.2% more skewed XCI profiles than asymptomatic carriers. The extent of
XCI skewing in blood tended to increase in line with the severity of muscle symptoms. Skewed XCI patterns were
found in at least one first-degree female relative in 78.6% of symptomatic carrier families. No mutations altering XCI
in the XIST gene promoter were found.
Conclusions: Skewed XCI is in many cases familial inherited. The extent of XCI skewing is related to phenotype
severity. However, the assessment of XCI by means of the AR methylation assay has a poor prognostic value,
probably because the methylation status of the AR gene in muscle may not reflect in all cases the methylation
status of the DMD gene.
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The dystrophinopathies are a group of X-linked muscle
diseases caused by mutations in the DMD gene. Clinical
phenotypes vary from asymptomatic high CK levels and
cramps to severe progressive skeletal and cardiac muscle
disorders such as Duchenne (DMD) and Becker (BMD)
muscular dystrophies, and X-linked dilated cardiomyop-
athy (XLCM) [1]. About one third of patients present
mental retardation [2]. Most disease-responsible muta-
tions are large intragenic rearrangements (exonic dele-
tions and duplications) that account for 65 to 75% of
cases, while the remaining cases are caused by single
point mutations or small rearrangements [3,4]. In most
patients, the clinical outcome can be predicted accord-
ing to the reading-frame rule. The majority of DMD
patients carry truncating mutations while BMD patients
usually carry in-frame mutations allowing the expression
of semi-functional dystrophins [1,5].
Female carriers of DMD mutations are usually asymp-
tomatic due to the X-linked inheritance of the disease.
However, symptomatic carriers can manifest a wide
spectrum of clinical symptoms ranging from myalgia and
cramps on exertion to severe disabling DMD-like muscle
weakness [6-11]. Onset of symptoms fluctuates from early
childhood to the fourth decade. The percentage of carriers
with clinical abnormalities varies among the series [7,12].
Hoogerwaard et al. found that 5% present regular myalgia
and cramps without muscle weakness, 17% show mild to
moderately severe muscle weakness, and 8% present dilated
cardiomyopathy, showing an average onset at 33 years [12].
Several disease-causing mechanisms have been impli-
cated in DMD/BMD manifesting carriers. These include
X-autosomal translocations disrupting the DMD gene
[13], mutations on both DMD alleles [10,14] and co-
occurrence of DMD mutations together with other gen-
etic abnormalities such as X-chromosome monosomy
[15-17], X-chromosome uniparental disomy [18] as well
as male pseudohermaphroditism caused by a mutation
in the androgen receptor gene [19]. However, the most
frequently reported mechanism to provoke symptoms in
DMD carriers is skewed X-inactivation, favouring the ex-
pression of the X chromosome with the DMD mutated
allele [8,20-22]. Although some studies suggest the use
of X-inactivation analysis for prognostic purposes, the
results of different reports are controversial [21,23,24].
In this study we aimed to investigate the prognostic
value of X-chromosome inactivation in a large series of
dystrophinopathy affected females presenting with a
wide spectrum of clinical phenotypes.
Materials and methods
Patients
We reviewed our database records of all dystrophinopa-
thy patients. The database includes patients with aclinical history compatible with dystrophinopathy, X-
linked family history of myopathy and/or a muscle bi-
opsy showing abnormal dystrophin immunostaining. We
identified 24 symptomatic carrier females referred from
different centres around Spain. For the present study we
included females with a confirmed DMD mutation or a
muscle biopsy showing altered dystrophin staining, who
manifest at least one of the following symptoms: myal-
gia, dilated cardiomyopathy, cognitive abnormalities or
muscle weakness. We retrospectively collected data
regarding clinical features, serum CK levels, cardiological
studies and muscle biopsy analysis. Patients were
grouped into different phenotype categories on the basis
of their clinical course.
Two control groups were selected for X-chromosome
inactivation (XCI) studies. The first control group con-
sisted of 40 asymptomatic female carriers who presented
28 different DMD mutations: 20 exonic deletions, 5 exo-
nic duplications, and 3 point mutations. The second
control group included 41 confirmed non-carrier
females from 28 unrelated DMD/BMD families with
known DMD mutations. The study was approved by the
Ethical Committe of Hospital de la Santa Creu i Sant
Pau (HSCSP), Barcelona. All participants gave their writ-
ten informed consent.
Muscle biopsy pathological analysis
A muscle biopsy was taken in 17 of the 24 symptomatic
carriers. These were processed for routine histological
and histochemical techniques, and for dystrophin immu-
nohistochemistry as described elsewhere [25].
Genetic analysis
DNA extracted from peripheral blood underwent DMD
mutational analysis using a combination of techniques.
Intragenic deletions and duplications were analyzed
using MLPA (P034 and P035 Salsa Kit, MRC-Holland).
Point mutation detection was done by whole gene se-
quencing using published primers [26]. When a muscle
biopsy was available, total mRNA was extracted and
purified from approximately 30 mg of muscle using
RNeasy Fibrous Tissue Mini Kit (Qiagen, Hilden, Ger-
many). Subsequently, muscle mRNA was retrotran-
scribed to cDNA by RT-PCR using polythymine primers
(Invitrogen, Carlsbad, NM). Complete DMD cDNA was
amplified and sequenced in twenty overlapping frag-
ments using published [27] and self-designed primers.
Splicing mutations were analyzed using predictive soft-
ware (Human Splice Finder and NNSPLICE). Nucleotide
positions were determined according to the standard
DMD reference sequence (GenBank accession number
NM_004006.2). In eight families segregation analysis of
the Xp21 locus was performed using microsatellite mar-
kers: 5’DYS-1, DXS1242, DXS1243, DXS206, DXS1238,
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cases (subjects #1, #2, #18 and #19) a karyotype was per-
formed before the DMD molecular analyses; all four
cases showed a normal 46XX karyotype.
X-chromosome inactivation (XCI) analysis
Methylation of the HpaII restriction site near a poly-
morphic (CAG)n repeat in the AR gene (Androgen Re-
ceptor) correlates with XCI [28]. We used HpaII
digestion followed by QF-PCR to determine the methy-
lation status of parental X chromosomes. Active alleles
are digested while the inactive alleles are not. The ratio
of undigested parental alleles gives the pattern of X-
chromosome inactivation.
For each sample, 500 ng of DNA were digested with
HpaII restriction endonuclease (New England Biolabs,
Ipswich, MA). Digested products together with non-
digested DNA were used as templates for amplification
of the AR polymorphic repeat using fluorescence la-
belled primers. PCR fragments were run in an ABI
3500xL Genetic Analyzer (Applied Biosymtems, Foster
City, CA). AR alleles were sized and quantified using
Genemapper software (Applied Biosymtems, Foster City,
CA). To correct preferential allele amplification, the al-
lele ratio in HpaII digested DNA was normalized using
the ratio of non-digested DNA. Monoallelic patients for
the AR repeat were reported as “non-informative”. Fol-
lowing previously published criteria, XCI ratios equal to
or less than 80:20 were considered “random” patterns
while ratios greater than 80:20 were considered “skewed”
patterns [29].
XCI studies were performed in lymphocyte DNA from
24 symptomatic carriers, 40 asymptomatic carriers and
41 non-carrier females. To detect familial XCI skewing,
analyses were also performed in at least one first-degree
female relative (mother, daughter or sister) in 15 of the
23 families with a symptomatic carrier. In 9 symptom-
atic carriers XCI analysis was also performed on muscle
DNA.
XIST minimal promoter mutation analysis
The expression of the non-coding gene XIST is involved
in the mechanisms that determine the choice of in-
active X chromosome [30]. Mutations c.-43C > A and
c.-43C > G, located in the XIST promoter region have
been associated to cause XCI skewing [31,32]. XIST
minimal promoter was amplified and sequenced in




Statistical comparison of proportion of skewed XCI be-
tween two groups was estimated using Fisher's ExactTest. Comparison of XCI ratios between two groups was
estimated using paired t test while comparison among
groups was done using one-way ANOVA, followed by
the Bonferroni post hoc test. P values lower than 0.05
were considered as statistically significant.
Results
Clinical presentation
From a total of 344 female carriers of DMD mutations
we identified 24 (7%) patients from 23 unrelated fam-
ilies who presented symptoms associated with dystro-
phinopathy. Two cases were identified within the same
family (subject #13, mother, and subject #14, daugh-
ter). Clinical features are summarized in Table 1. Clin-
ical presentations were highly heterogeneous and
included: isolated dilated cardiomyopathy (n = 2, 8.3%),
isolated cognitive abnormalities (n = 3, 12.5%), myalgia
without muscle weakness (n = 4, 16.7%), and mild to
severe muscle weakness (n = 15, 62.5%). Patients present-
ing muscle weakness were grouped into three different
phenotype categories: mild BMD-like (n = 7, 29%), severe
BMD-like (n = 5, 21%) and DMD-like (n = 2, 8.3%). Sub-
ject #3 presented with weakness at the age of 2 years and
was too young to be assigned to either DMD-like or se-
vere BMD-like. Muscle weakness was asymmetric in 6
cases (subjects #6, #9, #10, #13, #14 and #15). Age of
onset varied from 2 to 74 years (median: 17.5; mean:
21.7). The most common presenting symptom was
muscle weakness (n = 14, 58.3%) followed by myalgia,
cramps and/or exercise intolerance (n = 8, 33.3%).
Cognitive abnormalities were found, in isolation or to-
gether with muscle weakness, in 5 cases (20.8%). These
abnormalities ranged from behavioural issues to severe
global developmental delay. Subject #1, who presented a
severe DMD-like phenotype, showed severe cognitive
impairment with comprehensive and expressive language
almost absent. Subjects #5, #19 and #20 presented with
learning difficulties or poor academic performance
showing mild mental retardation in a WISC-IV test,
while subject #18 presented poor social and communica-
tion skills but no mental retardation. In subjects #18,
#19 and #20, cognitive abnormalities were the only clin-
ical symptoms. In these subjects, other aetiologies of
mental retardation such as metabolic diseases, brain
malformations, chromosomal disorders or fragile X syn-
drome were considered. These were ruled out by hor-
mone and metabolic profiling in blood and urine
(subjects #18, #19 and #20), neuroimaging studies (sub-
jects #19 and #20), karyotype analysis (subjects #18 and
#19) and FMR1 molecular analysis (subject #19). Sub-
ject #18 presented a BMD affected brother while in sub-
jects #19 and #20, in absence of previous family history
of neuromuscular disease, elevation of CK levels or a
muscle biopsy showing abnormal dystrophin expression
Table 1 Clinical features of symptomatic carriers of DMD mutations
Patient Age of
onset
Phenotype Presenting symptoms Age at most
recent exam
Clinical symptoms at most recent exam CK levels (age) Affected
relative
1 2 DMD-like Global developmental delay, weakness 13 Severe mental retardation, severe weakness,
wheelchair-bound at 13, normal echocardiogram
22055 (13) no
2 4 DMD-like Weakness, calf pseudohypertrophy 14 Severe weakness, wheelchair-bound at 10, normal echocardiogram 12000 (4) no
3 2 D/BMD-like Frequent falls, seizures 5 Mild weakness in lower limbs, normal echocardiogram n/p no
4 12 Severe BMD-like Weakness 29 Severe weakness and atrophy n/p DMD
5 4 Severe BMD-like Exercise intolerance, weakness,
poor school performance
12 Incomplete Gower's sign, herculean appearance,
calf pseudohypertrophy, mild mental retardation
7678-333 (8–12) no
6 7 Severe BMD-like Asymmetric weakness 11 Asymmetric weakness, more severe in shoulder than
in pelvic girdle, normal echocardiogram
n/p no
7 20 Severe BMD-like Weakness 24 Severe weakness of upper and lower limbs, need a
wheelchair for long walks, normal echocardiogram
1700 (24) no
8 4 Severe BMD-like Frequent falls, weakness 26 Severe weakness, walks with mayor difficulties,
calf pseudohypertrophy, normal echocardiogram
5331 (22) no
9 28 Mild BMD-like Asymmetric weakness 32 Moderate unilateral weakness of right limbs, normal echocardiogram 1500 (32) DMD
10 41 Mild BMD-like Weakness, calf pseudohypertrophy 42 Mild weakness, asymmetric in shoulder, asymmetric
atrophy of posterior leg compartment
6654 (42) DMD
11 18 Mild BMD-like Myalgia/cramping, calf pseuhypertrophy 49 Moderate muscle weakness, normal echocardiogram 1527 (49) DMD
12 30 Mild BMD-like Myalgia, weakness 38 Moderate muscle weakness, normal echocardiogram 1288 (30) DMD
13 31 Mild BMD-like Finding elevated CK prompted a neurological
examination revealing mild weakness
51 Moderate asymmetric weakness 2857 (31) DMD
14 13 Mild BMD-like Detecting weakness in her mother prompted
neurological examination finding mild weakness
33 Moderate asymmetric weakness, calf pseuhypertrophy 10530-6950 (13–33) DMD
15 39 Mild BMD-like Frequent falls, myalgia/cramping, weakness 51 Moderate asymmetric weakness, more affected in
lower limbs, mild non-specific echocardiographic
changes and bundle branch block
1770-590 (43–51) DMD
16 66 DCM Dilated cardiomyopathy with severe
ventricular dysfunction
69 Dilated cardiomyopathy with no muscle weakness n/p DMD
17 74 DCM Dilated cardiomyopathy 77 Dilated cardiomyopathy with no muscle weakness n/p DMD
18 7 Behavioural issues Abnormal behaviour, elevated CK levels 12 Behavioural abnormalities without mental retardation,
no muscle weakness, normal echocardiogram
3000 (7) BMD
19 4 MR Delayed speech development,
abnormal behaviour, elevated CK levels
8 Mild mental retardation, no muscle weakness 1137 (4) no
20 4 MR Learning difficulties, elevated CK levels 18 Mild mental retardation, no muscle weakness 1193 (14) no
21 31 Myalgia Precordial pain, myalgia 36 Regular myalgia, no muscle weakness, normal echocardiogram 897 (36) DMD
22 33 Myalgia Myalgia 34 Regular myalgia, no muscle weakness 450 (34) DMD
23 17 Myalgia Exercise intolerance 19 Regular myalgia, no muscle weakness n/p no
24 30 Myalgia Myalgia 32 Regular myalgia, no muscle weakness n/p no




















Table 2 Summary of genetic findings and muscle biopsy features in symptomatic carriers of DMD mutations












1 DMD-like Deletion exons 1–44
(c.(?_-244)_6438 + ?del, frameshift)
Severe dystrophic pattern Generalized absence 93:7 n/p maternal paternal yes
2 DMD-like Subexonic deletion/insertion
exon 17 (c.2095delinsTC, frameshift)
End-stage muscular dystrophy n/p 100:0 51:49 paternal n/p no
3 D/BMD-like Stop exon 8(c.724C > T, p.Gln242X) Severe dystrophic pattern Generalized absence 100:0 61:39 paternal n/p yes
4 Severe BMD-like Splice site exon 27
(c.3786 + 1G>A, predicted frameshift)
Moderate dystrophic pattern Mosaic pattern 94:6 81:19 paternal maternal yes
5 Severe BMD-like Deletion exon 68
(c.9808-?_9974 + ?del, frameshift)
Moderate dystrophic pattern Mosaic pattern 69:31 n/p maternal n/p yes
6 Severe BMD-like Stop exon 41
(c.5893C > T, p.Gln1965X)
Severe dystrophic pattern Reduction/absence in
isolated fibres
74:26 52:48 n/i n/p yes
7 Severe BMD-like Deletion exons 5–7
(c.265-?_649 + ?del, frameshift)
Severe dystrophic pattern Mosaic pattern 81:19 87:12 n/p n/p n/p
8 Severe BMD-like Deletion exon 44
(c.6291-?_6438 + ?del, frameshift)
Moderate dystrophic Mosaic pattern with
predominance of negative fibres
100:0 n/p n/p n/p n/p
9 Mild BMD-like Deletion exons 43–45
(c.6118-?_6614 + ?del, frameshift)
Mild dystrophic pattern Mosaic pattern n/i n/p n/p n/p n/p
10 Mild BMD-like Deletion exons 45–50
(c.6439-?_7309 + ?del, frameshift)
Moderate dystrophic pattern. Mosaic pattern 71:29 n/p n/i maternal no
11 Mild BMD-like Deletion exons 53–54
(c.7661-?_8027 + ?del, frameshift)
Mild dystrophic pattern Reduction/absence in
isolated fibres
81:19 n/p n/i maternal no
12 Mild BMD-like Duplication exons 50–55
(c.7201-?_8217 + ?dup,
predicted in-frame)
n/p n/p n/i n/p n/p maternal n/p
13 Mild BMD-like Splice site exon 48
(c.6913-1G > A, frameshift)
Mild dystrophic pattern Mosaic pattern 81:19 53:47 maternal maternal yes
14 Mild BMD-like Splice site exon 48
(c.6913-1G > A, frameshift)
n/p n/p 72:28 n/p paternal maternal yes
15 Mild BMD-like Deletion exons 48–50
(c.6913-?_7309 + ?del, frameshift)
Mild dystrophic pattern Mosaic pattern 52:48 40:60 n/p n/p n/p
16 DCM Deletion exon 44
(c.6291-?_6438 + ?del, frameshift)
n/p n/p 99:1 n/p n/i n/p Yes
17 DCM Deletion exons 46–52
(c.6615-?_7660 + ?del, frameshift)
n/p n/p 63:37 n/p n/p n/p n/p
18 Behavioural issues Duplication exons 13–27
(c.1483-?_3786 + ?dup,
predicted in-frame)
Myopathic changes Normal 99:1 97:3 paternal maternal Yes
19 MR Subexonic deletion exon 46
(c.6638delT, frameshift)




















able 2 Summary of genetic findings and muscle biopsy features in symptomatic carriers of DMD mutations (Continue
0 MR Deletion exons 46–55
(c.6615-?_8217 + ?del, frameshift)
n/p n/p 100:0 n/ paternal maternal n/i
1 Myalgia Duplication exons 38–43
(c.5326-?_6290 + ?dup,
predicted frameshift)
n/p n/p 74:26 n/ paternal maternal yes
2 Myalgia Deletion exons 10–43
(c.961-?_6290 + ?del, frameshift)
n/p n/p 51:49 n/ n/p n/p n/p
3 Myalgia Deletion exon 7
(c.531-?_649 + ?del, frameshift)
Myopathic changes Reduction/absence in
isolated fibres
78:22 n/ n/p n/p n/p
4 Myalgia Deletion exons 3–13
(c.94-?_1602 + ?del, in-frame)
Myopathic changes Mosaic pattern 50:50 n/ n/p n/p n/p































Figure 1 Dystrophin immunostaining in muscle biopsy sections from representative symptomatic carriers. A) D/BMD-like subject #3, B)
severe BMD-like subject #4, C) severe BMD-like subject #6, D) severe BMD-like subject #8, E) mild BMD-like subject #13, F) subject #19 presenting
mild mental retardation but no muscle weakness. No association was found between dystrophin abnormalities and clinical phenotype.
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clude that the behavioural abnormalities of subject #18
were aetiologically independent of the dystrophinopathy.
However, her BMD affected brother presented mild
muscle symptoms and mental retardation with autistic
behaviour indicating that the behavioural issues could be
related to the dystrophinopathy.
Echocardiographic studies were performed in 14 cases
and abnormalities were detected in three (21.4%). Severe
cardiac dysfunction caused by dilated cardiomyopathy
(DCM) was found in two cases (subjects #16 and #17)
that did not present accompanying muscle symptoms.
Onset of symptoms in these two patients was 66 and
74 years. Subject #15 showed mild non-specific echocar-
diographic abnormalities and a bundle branch block on
EKG but no signs of cardiac failure.
Muscle biopsy pathological findings
Muscle biopsy was performed in 17 cases. Results are sum-
marized in Table 2 and Figure 1. Abnormal pathological
features were found in all analyzed cases, and included vari-
ation in fibre size, increased numbers of internal nuclei,
muscle fibre necrosis and regeneration, and variable degree
of endomysial fibro-fatty tissue proliferation. Non-specific
myopathic changes were detected in four patients, whereasmild to severe dystrophic changes were found in the
remaining thirteen. Immunohistochemical analysis revealed
a mosaic pattern of dystrophin-positive and reduced or
absent dystrophin fibres in 9 cases (53%). In 4 cases only
isolated dystrophin-negative fibres were observed. Normal
dystrophin staining was found in a single patient (#18) who
presented behavioural issues as the only symptom. General-
ized absence of dystrophin expression was observed in two
patients (subjects #1 and #3), both of whom suffered from
muscle weakness from early childhood.
Related probands and DMD mutation spectrum
Among the 24 symptomatic carriers 13 had a previous
family history of dystrophinopathy affected males
(54.2%) while the 11 remaining cases were isolated
symptomatic carriers (45.8%). The vast majority of cases
with previous family history had DMD affected relatives
(12/13, 92.3%). Only subject #18, who presented behav-
ioural issues as the only clinical symptom, had a BMD
affected brother. Most cases with no previous family his-
tory presented mutations predominantly associated to
the DMD phenotype according to the Leiden Open Vari-
ation Database (LOVD, www.dmd.nl).
Twenty-two different DMD mutations were identified,
all in heterozygous state. These are listed in Table 2 and
Figure 2 X-chromosome inactivation patterns in blood. A)Distribution of XCI patterns among non-carrier females (n = 41), asymptomatic
carriers (n = 40) and symptomatic carriers excluding patients presenting only myalgia (n = 18). For each group, the five parameters are the lowest
observation, lower quartile, median, upper quartile, and highest observation. B) Distribution of XCI patterns among symptomatic carriers
according to clinical phenotype. Individual XCI data, mean and standard deviation are shown. The extent of XCI skewing in blood tended to
increase with increasing severity of muscle symptoms.
Figure 3 Inheritance of DMD mutation, parental origin of most inactivated X-chromosome and familial skewed XCI in family of
subject #1. A) Family pedigree. Haplotype analysis of Xp21 locus indicates that the mutation is located at the paternal X-chromosome.
B) Genemapper traces of non-digested and HpaII digested AR alleles in blood. Methylated status of the AR revealed that both mother and
daughter present highly skewed XCI. Maternal X-chromosome is preferentially inactivated in affected daughter indicating that the paternal X-
chromosome carrying the DMD mutated allele is active.
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tions (14%) and 6 point mutations (27%). Point muta-
tions consisted of two nonsense mutations, two small
deletions/insertions and two splicing mutations. Subjects
#2, #4, #18 and #19 presented novel mutations according
to LOVD. Most patients carried predicted frameshift or
nonsense mutations (87.5%, 21/24). In-frame mutations
included: duplication 13–27 (subject #18), not previously
described, duplication 50–55 (subject #12) and, deletion
3–13 (subject #24). The latter two mutations were both
associated mainly with DMD phenotype according to
LOVD.
Splice site mutations were analyzed at muscle cDNA
level or by predictive software in order to identify pre-
mRNA splicing defects. The c.6913-1G > A mutation,
identified in patients #13 and #14, a mother and daugh-
ter, destroyed the putative acceptor splice site of exon
48. At the muscle cDNA level the mutation was
observed to provoke a single base deletion due to the
creation of a new acceptor site at position c.6913. The
c.3786 + 1G > A mutation identified in subject #4
destroyed the putative donor splice site of exon 27. Al-
though this mutation was not analyzed at the muscle
cDNA level, the presence of a cryptic donor splice site
located at position c.3786 + 53 possibly provoked the re-
tention of an intronic fragment of 52 bp.
In four cases (#3, #6, #13 and #19) mutation analysis
was performed both at genomic and muscle cDNA level.
In subjects #6, #13 and #19, both wild-type and mutated
transcripts were detected in muscle cDNA. In subjectFigure 4 Preferential expression of the DMD mutated allele correlates
A) Automated sequence analysis of DMD gene exon 8 showing the nonse
cDNA level, only the mutated transcript was detected. C) Genemapper trac
Blood DNA presented a skewed XCI pattern of 100:0 while muscle DNA ex#3, only the mutated transcript carrying a nonsense mu-
tation was detected, while at genomic level, the mutation
was in heterozygous state (Figure 2).
X-chromosome inactivation studies (XCI)
XCI analysis was performed in lymphocyte DNA of the
24 symptomatic carriers, 40 non-symptomatic carriers
and 41 non-carrier females. Results are summarized in
Table 2 and Figure 3. XCI studies were informative in 22
symptomatic carriers. Among these, the mean XCI ratio
was 80:20 ± 16.8 and a skewed XCI pattern was found in
12 cases (54.6%). If we do not consider patients present-
ing myalgia as a true symptomatic carriers as previously
published criteria [10,12], skewed XCI among symptom-
atic carriers (n = 18) increased to 66.7% with a mean
XCI ratio of 84:16 ± 14.9. Asymptomatic carriers and
non-carrier females presented similar distribution of
XCI ratios: among asymptomatic carriers, 17.5% pre-
sented skewed XCI with a mean ratio of 66:34 ± 13.1,
while among non-carrier females skewed XCI was found
in 12.2% with a mean ratio of 66:34 ± 11.9. Differences
in the XCI ratio and proportion of skewed cases between
symptomatic carriers and asymptomatic carriers or non-
carrier females were statistically significant (p values
<0.001 by paired t-test and Fisher's Exact Test).
The extent of XCI skewing in blood tended to in-
crease in line with the severity of symptoms among
phenotype groups presenting skeletal muscle involve-
ment (Figure 3B). While all patients with myalgia
showed random XCI (mean ratio: 62:38), skewed XCIwith blood XCI but not with muscle XCI in subject #3.
nse mutation c.724C > T/p.Gln242X in heterozygous state. B) At muscle
es of non-digested and HpaII digested AR alleles in blood and muscle.
hibited a random pattern of 61:39.
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phenotype (mean ratio: 71:29), in 60% of patients with se-
vere BMD-like phenotype (mean ratio: 84:16) and in all
DMD-like cases (including subject #3, mean ratio: 98:2).
However, these differences only reached statistical signifi-
cance between DMD-like and myalgia groups. Skewed
XCI was present in 80% of cases showing cognitive ab-
normalities (mean ratio 90:10). One of the two patients
who presented a DCM showed a random pattern and the
other showed a highly skewed pattern (mean ratio 81:19).
XCI analysis was also performed in muscle DNA in
nine symptomatic carriers (Table 2). Similar XCI ratios
between blood and muscle were found only in two cases,
while the remaining seven exhibited significant differ-
ences. From the seven cases showing skewed XCI in
blood only three presented a skewed pattern in muscle
(43%). In all cases the most active X-chromosome was
the same in blood and muscle.
Parental origin of most inactivated X-chromosome and
inheritance of DMD mutation
The parental origin of X chromosomes was determined
by comparing AR alleles in the patient with those of her
parents, while inheritance of DMD mutation was estab-
lished either by carrier status of patient’s mother and/or
by segregation analysis of Xp21 locus using polymorphic
microsatellites (Table 2 and Figure 4). In most cases,
most inactivated X chromosome was from paternal ori-
gin (8/11, 73%) while DMD mutation was inherited from
the mother (10/11, 91%). In 7 of 8 cases, mutant DMD
allele segregated with the most unmethylated AR allele
(active X-chromosome). However, two of them did not
reach a skewed XCI pattern (>80:20) in blood.
Familial skewed X-chromosome inactivation and analysis
of the XIST promoter
XCI studies in at least one first degree female relative
(mother, daughter or sister) were performed in 15 of the
23 different families with symptomatic carriers (Figure 4).
Evidence of familial skewed XCI was found in eleven of
fourteen families with informative AR alleles (78.6%).
Surprisingly, mothers of three symptomatic carriers
showing random XCI in blood (subjects #5, #6 and #21)
exhibited skewed XCI. The promoter region of XIST
non-coding gene was screened in all symptomatic car-
riers but no mutations were detected.
Discussion
We report the largest series of DMD symptomatic car-
riers, consisting of 24 cases covering a wide spectrum of
clinical phenotypes. The main mechanism found to pro-
voke symptoms in these patients was skewed XCI
favouring expression of the DMD-mutated allele. We
provide data consistent with the hypothesis that theextent of XCI skewing is related to phenotype severity
and that skewed XCI patterns are in most cases familial
inherited. We also describe what is, to our knowledge,
the first report of DMD female carriers presenting
cognitive impairment but no muscle weakness,
broadening the clinical phenotypes associated with
dystrophinopathy.
In line with previous reports [33], isolated symptom-
atic carriers were relatively frequent, suggesting that dys-
trophinopathy should always be considered in females
suffering from a myopathy of unknown cause, even in
the absence of an X-linked family history. In these cases
dystrophin immunostaining on muscle sections remains
the best diagnostic tool even though an exon copy num-
ber screening technique (such as MLPA) can be consid-
ered prior to muscle biopsy. Muscle biopsies showed
variable pathological features in all studied cases. Fur-
thermore, dystrophin abnormalities were found in all
but one case. In accordance with previous publications
[6,20,34], we did not find a correlation between dys-
trophin expression and clinical phenotype, although the
most affected subjects showed generalized dystrophin
absence (Figure 1).
Our findings confirm that symptomatic carriers
present a wide clinical variability ranging from nearly
asymptomatic forms to disabling DMD-like phenotypes.
The progression of muscle weakness among symptom-
atic carriers correlates with onset of symptoms. Onset
during the first decade was associated in all cases with
rapid progression leading to severe phenotypes (DMD-
like or severe BMD-like), while later onset, from the
third decade onwards, was associated with mild progres-
sion. However, patients presenting onset of symptoms
during the second decade exhibited variable severity.
Subject #7 presented onset of weakness at 20 years with
rapid progression leading to wheelchair support five
years later, whereas subject #11 who manifested the first
symptoms at 18 years is still able to walk at the age of
49 years. In accordance with previous observations
[10,12,33], muscle weakness was asymmetric in 40% of
our patients. Asymmetry may be caused by somatic mo-
saicism [35] or reflect different XCI patterns between
different muscle groups and tissues. In keeping with the
later hypothesis, most of our cases presenting muscle
weakness and random XCI in blood showed asymmetric
distribution of weakness (4/5). Five patients presented
symptoms without skeletal muscle involvement: two
subjects presented isolated dilated cardiomyopathy while
three showed cognitive abnormalities.
Cognitive abnormalities, observed in five patients in
isolation or together with muscle weakness, ranged from
behavioural issues to severe global developmental delay.
Risk of cognitive deficits among DMD patients is thought
to be the result of the cumulative loss of dystrophin
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ment [36]. According to this hypothesis, mutations in
three subjects (#5, #19 and #20) were predicted to destroy
most dystrophin isoforms. Nevertheless, in the other two
subjects (subjects #1 and #18) only long isoforms were
predicted to be affected. It is of particular note that four of
the five cases presenting cognitive deficits showed highly
skewed XCI patterns in blood independently of muscle
symptoms. This could indicate that the central nervous
system is more affected than muscle by reduced dys-
trophin expression due to biased XCI.
Skewed XCI favouring expression of the DMD-
mutated X chromosome has been proposed as the main
mechanism accounting for symptoms in symptomatic
carriers without chromosomal rearrangements. However,
results concerning the use of XCI as a prognostic marker
are controversial. While some studies found that the
great majority of symptomatic cases exhibited skewed
profiles [20-22] others found that XCI is not a reliable
measure to predict whether carrier female will develop
symptoms [6,10,24]. Most women in the normal popula-
tion present a random XCI pattern in peripheral blood.
However, a skewed pattern is present in 8.8% of females,
increasing up to 14.2% in adult women [29]. We found a
distribution of XCI ratios in blood among control groups
(asymptomatic carriers and non-carrier females) similar
to those described in the normal adult population [29].
Regarding our group of symptomatic carriers, excluding
those manifesting only myalgia, the number of skewed
cases was 49.2% higher (mean XCI ratio 18% higher)
than in asymptomatic carriers. In cases presenting
skeletal muscle involvement, the extent of XCI skewing
in blood tended to increase in line with the severity of
symptoms (Figure 3B). However, assessing XCI through
the AR methylation assay seems to have a poor prog-
nostic value, since some subjects showing similar XCI
patterns exhibited different phenotype severity. Further-
more, four subjects (#16, #18, #19 and #20) with highly
skewed patterns presented no skeletal muscle involve-
ment. When XCI analysis was performed on muscle
DNA we observed no correlation between the extent of
XCI skewing and clinical severity or proportion of
dystrophin-negative fibres. As previously described
[6,23], in most cases XCI profile in muscle differed sig-
nificantly from that found in blood. This could reflect a
biochemical and genetic normalization process in skel-
etal muscle [25,37,38], or tissue-specific differences in
XCI or in the methylation status of the AR gene. In
keeping with the latter hypothesis, in subject #3 the
preferential expression of the DMD mutated allele cor-
related with the XCI ratio in blood but not with that
in muscle (Figure 2). This case suggests that the
methylation status of the AR gene in muscle may not
reflect in all cases that of the DMD gene.Soltanzadeh et al. [10] found that DMD deletions or
duplications were significantly more associated with
skewed XCI compared with point mutations suggesting
a correlation between XCI and mutation class. Analysing
our data, we found that skewed XCI was more frequent
in patients with point mutations (5/7, 71.4%) compared
with those carrying deletions or duplications (7/15,
46.7%). However, these differences do not reach statis-
tical significance in a Fisher’s Exact Test suggesting that
the DMD mutation class is not involved in the develop-
ment of X inactivation skewness.
We found evidence of familial XCI skewing in 78.6%
of analyzed families suggesting that in many cases this
may be under genetic control. X inactivation is a com-
plex process restricted to early embryogenesis in which
an X chromosome is silenced at random depending on
the stable expression of the cis-acting XIST gene [30].
Skewed X inactivation may be caused primarily by pre-
ferential silencing of one specific X chromosome due to
genetic factors, or by chance due to the very limited
number of precursor cells present at the moment of in-
activation [39]. In X chromosome defects, skewing can
also be secondary during development due to post-
inactivation selection. Selection tends to preserve gene
dosage: in balanced X:autosome translocations the nor-
mal X is generally inactivated while in X deletions the
inactivated chromosome is the deleted X [39]. Muta-
tions in the XIST gene promoter have been reported
to cause primary non-random X-chromosome inactiva-
tion [31,32]. We analyzed the XIST promoter in all
patients but no changes were detected. Other loci on the
X chromosome have been associated with familial skew-
ing of X inactivation, suggesting that factors other than
XIST may control the primary choice of X chromosome
or be secondarily involved in cell survival [40,41].
We consider that it could be clinically important to
identify the genetic factors that alter random X inactiva-
tion in heterozygous females expressing X-linked recessive
traits such as dystrophinopathy.
The reduced sample size and lack of systematic case
collection limit the generalizability of the results.
Conclusion
Our results demonstrate that the extent of XCI skewing
is related to phenotype severity in symptomatic female
carriers of dystrophinopathy. The methylation status of
the AR gene in muscle may not reflect in all cases the
methylation status of the DMD gene, conferring a poor
prognostic value to the AR methylation assay for the as-
sessment of XCI. Furthermore, skewed XCI is in many
cases familial inherited.
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